Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$2.49B |
| 2 |
NVIDIA
NVDA
|
+$2.19B |
| 3 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$1.94B |
| 4 |
TSMC
TSM
|
+$728M |
| 5 |
UnitedHealth
UNH
|
+$705M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$775M |
| 2 |
AbbVie
ABBV
|
+$540M |
| 3 |
Delta Air Lines
DAL
|
+$434M |
| 4 |
Eli Lilly
LLY
|
+$433M |
| 5 |
DexCom
DXCM
|
+$433M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 4.89% |
| 2 | Healthcare | 2.92% |
| 3 | Financials | 2.71% |
| 4 | Consumer Discretionary | 2.52% |
| 5 | Industrials | 2.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11401
PUT
Paysign
PAYS
$708M
| $129K | ﹤0.01% |
25,000
-7,400
| -23% | -$39.9K |
|
11402
PUT
Carlyle Secured Lending
CGBD
$742M
| $129K | ﹤0.01% |
10,300
-12,800
| -55% | -$159K |
|
|
TSLG
11403
PUT
Leverage Shares 2X Long TSLA Daily ETF
TSLG
$34.4M
| $129K | ﹤0.01% |
13,800
+500
| +4% | +$5K |
|
11404
PUT
Humacyte
HUMA
$192M
| $129K | ﹤0.01% |
133,900
+60,600
| +83% | +$85.8K |
|
|
DHF
11405
BNY Mellon High Yield Strategies Fund
DHF
$172M
| $128K | ﹤0.01% |
51,765
+13,572
| +36% | +$34.4K |
|
|
MVO
11406
DELISTED
MV Oil Trust
MVO
| $128K | ﹤0.01% |
103,516
+84,776
| +452% | +$277K |
|
11407
Vivid Seats
SEAT
$87.7M
| $127K | ﹤0.01% |
17,671
-33,776
| -66% | -$332K |
|
11408
PUT
Black Diamond Therapeutics
BDTX
$112M
| $127K | ﹤0.01% |
+52,400
| New | +$186K |
|
|
NAGE
11409
CALL
Niagen Bioscience
NAGE
$243M
| $127K | ﹤0.01% |
20,000
-34,500
| -63% | -$240K |
|
11410
Nuveen Municipal High Income Opportunity Fund
NMZ
$2.21B
| $127K | ﹤0.01% |
+12,468
| New | +$131K |
|
11411
CALL
Avita Medical
RCEL
$198M
| $127K | ﹤0.01% |
36,700
+3,100
| +9% | +$12.4K |
|
11412
Cibus
CBUS
$144M
| $126K | ﹤0.01% |
72,604
+51,456
| +243% | +$76.8K |
|
11413
Nuveen Dynamic Municipal Opportunities Fund
NDMO
$601M
| $126K | ﹤0.01% |
+12,524
| New | +$131K |
|
11414
CALL
Clean Energy Fuels
CLNE
$396M
| $126K | ﹤0.01% |
60,000
+1,600
| +3% | +$3.91K |
|
11415
CALL
Solid Biosciences
SLDB
$852M
| $126K | ﹤0.01% |
22,300
+7,400
| +50% | +$40.1K |
|
|
FIRY
11416
Firy Inc
FIRY
$156M
| $126K | ﹤0.01% |
29,177
-11,531
| -28% | -$71.2K |
|
|
BTOC
11417
Armlogi Holding Corp
BTOC
$13M
| $126K | ﹤0.01% |
+241,823
| New | +$154K |
|
11418
PUT
Talos Energy
TALO
$2.32B
| $126K | ﹤0.01% |
11,400
-49,200
| -81% | -$515K |
|
11419
PUT
MBIA
MBI
$265M
| $125K | ﹤0.01% |
17,500
-11,500
| -40% | -$83.1K |
|
11420
Orchestra BioMed
OBIO
$250M
| $125K | ﹤0.01% |
30,175
-23,827
| -44% | -$96.1K |
|
|
GRFS
11421
Grifois
GRFS
$5.39B
| $125K | ﹤0.01% |
13,343
-224,213
| -94% | -$2.04M |
|
11422
PUT
Alpha Tau Medical
DRTS
$1.2B
| $125K | ﹤0.01% |
+25,200
| New | +$106K |
|
11423
CALL
Clarivate
CLVT
$1.2B
| $125K | ﹤0.01% |
37,300
+300
| +0.8% | +$1.07K |
|
11424
PUT
FTC Solar
FTCI
$46.3M
| $124K | ﹤0.01% |
+11,400
| New | +$104K |
|
|
RWT
11425
PUT
Redwood Trust
RWT
$578M
| $124K | ﹤0.01% |
22,400
-65,500
| -75% | -$360K |
|
Similar funds
Citadel Advisors's Q4 2025 Portfolio in Review
As of Q4 2025, Citadel Advisors held 14,701 positions worth $666B, up 1.3% from $657B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Citadel Advisors's Q4 2025 filing shows 2,078 new, 5,000 increased, 5,362 reduced and 2,191 closed positions. Its largest new stake was Medline Inc: 6,006,339 shares worth $252M. The largest sale was Meta Platforms (Facebook), an estimated $775M.
By sector, the portfolio is most concentrated in Technology at 4.9% of assets, up from 3.8% a quarter earlier, followed by Healthcare and Financials.
- Citadel Advisors's largest Q4 2025 buy was Medline Inc: 6,006,339 shares worth $252M.
- Citadel Advisors added most to Amazon in Q4 2025, an estimated $2.49B increase.
- Citadel Advisors's biggest Q4 2025 reduction was Meta Platforms (Facebook), cutting an estimated $775M.
- Citadel Advisors fully exited WEX in Q4 2025, selling an estimated $131M.
- Citadel Advisors's ten largest holdings make up 23% of its $666B portfolio in Q4 2025.
- Citadel Advisors opened 2,078 new positions and closed 2,191 in Q4 2025.
- Citadel Advisors's portfolio value rose 1.3% quarter-over-quarter to $666B.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.